HUP0301740A2 - Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások - Google Patents

Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások

Info

Publication number
HUP0301740A2
HUP0301740A2 HU0301740A HUP0301740A HUP0301740A2 HU P0301740 A2 HUP0301740 A2 HU P0301740A2 HU 0301740 A HU0301740 A HU 0301740A HU P0301740 A HUP0301740 A HU P0301740A HU P0301740 A2 HUP0301740 A2 HU P0301740A2
Authority
HU
Hungary
Prior art keywords
polypeptides
breast cancer
preparations
subject
cells
Prior art date
Application number
HU0301740A
Other languages
English (en)
Inventor
Davin C. Dillon
Susan L. Harlocker
William T. Hepler
Yuqiu Jiang
Jennifer L. Mitcham
Jiangchun Xu
Original Assignee
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/551,621 external-priority patent/US6844325B2/en
Priority claimed from US09/604,287 external-priority patent/US6586572B2/en
Application filed by Corixa Corporation filed Critical Corixa Corporation
Publication of HUP0301740A2 publication Critical patent/HUP0301740A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tárgyát emlődaganat-protein vagy variánsa legalább egyimmunogén részletét tartalmazó izolált polipeptidek, a polipeptidekettartalmazó fúziós proteinek és a polipeptidekre specifikusellenanyagok, a polipeptideket kódoló izolált polinukleotidok, apolinukleotidokat tartalmazó expressziós vektorok, valamint azexpressziós vektorokkal transzfektált gazdasejtek képezik. A találmánytárgyát képezik továbbá a polipeptideket, polinukleotidokat, fúziósproteineket, valamint monoklonális ellenanyagokat tartalmazó, emlőrákpáciensbeli kialakulásának megakadályozására és kezelésére szolgálógyógyászati készítmények és immunogén készítmények. A találmánytárgyát képezik továbbá emlőrák páciensbeli jelenlétének kimutatásáraés előrehaladásának monitorozására szolgáló eljárások és diagnosztikaireagenskészletek. A találmány tárgyát képezik továbbá az említettpolipeptidekkel vagy polinukleotidokkal történt inkubálássalelőállított proliferált T-sejtek és antigénbemutató sejtek, az azokattartalmazó készítmények, valamint a T-sejtek, antigénbemutató sejtekés készítmények emlőrák gyógykezelésére történő alkalmazása. Ó
HU0301740A 2000-04-17 2001-04-12 Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások HUP0301740A2 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/551,621 US6844325B2 (en) 1998-12-28 2000-04-17 Compositions for the treatment and diagnosis of breast cancer and methods for their use
US09/590,751 US6756477B1 (en) 1998-12-28 2000-06-08 Compositions and methods for the therapy and diagnosis of breast cancer
US09/604,287 US6586572B2 (en) 1998-12-28 2000-06-22 Compositions and methods for the therapy and diagnosis of breast cancer
US09/620,405 US6528054B1 (en) 1998-12-28 2000-07-20 Compositions and methods for the therapy and diagnosis of breast cancer
PCT/US2001/012164 WO2001079286A2 (en) 2000-04-17 2001-04-12 Compositions and methods for the therapy and diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
HUP0301740A2 true HUP0301740A2 (hu) 2004-06-28

Family

ID=27504757

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301740A HUP0301740A2 (hu) 2000-04-17 2001-04-12 Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások

Country Status (14)

Country Link
US (1) US6528054B1 (hu)
EP (1) EP1299417A2 (hu)
JP (1) JP5053497B2 (hu)
CN (1) CN1646563A (hu)
AU (1) AU2001255369A1 (hu)
BR (1) BR0110091A (hu)
CA (1) CA2406213A1 (hu)
HU (1) HUP0301740A2 (hu)
MX (1) MXPA02010244A (hu)
NO (1) NO20024972L (hu)
NZ (1) NZ521865A (hu)
PL (1) PL365244A1 (hu)
RU (1) RU2344831C2 (hu)
WO (1) WO2001079286A2 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7414112B2 (en) * 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US7354992B2 (en) * 1999-11-30 2008-04-08 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
EP1577323B1 (en) 2002-12-26 2013-07-10 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
US20070178532A1 (en) * 2003-03-24 2007-08-02 The Gov.Of The Us As Represented By The Secretary Identification, quantification, and characterization of t cells and t cell antigens
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CA2571420A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
CA2621982C (en) * 2005-09-07 2017-11-28 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
CN101974088B (zh) * 2010-11-03 2014-04-02 中国人民解放军军事医学科学院基础医学研究所 乳腺珠蛋白单克隆抗体及其在乳腺癌诊断中的应用
WO2013016126A1 (en) * 2011-07-22 2013-01-31 The General Hospital Corporation Therapeutic nanoparticles and methods of use thereof
JP2016214239A (ja) * 2015-05-15 2016-12-22 国立大学法人高知大学 膵がんマーカー
EP3797790A1 (en) 2015-12-04 2021-03-31 Boehringer Ingelheim International GmbH Biparatopic polypeptides antagonizing wnt signaling in tumor cells
WO2017120274A1 (en) * 2016-01-08 2017-07-13 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from protocadherin fat1 as cancer biomarkers
JP6995197B2 (ja) 2017-10-12 2022-02-04 イー アンド エス ヘルスケア カンパニー リミテッド チオレドキシン１エピトープおよびこれに特異的に結合する単一クローン抗体
TWI709188B (zh) 2018-09-27 2020-11-01 財團法人工業技術研究院 基於機率融合的分類器、分類方法及分類系統
RU2736163C1 (ru) * 2019-05-29 2020-11-12 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ интраоперационной диагностики рака молочной железы
CN112724233B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-13、制法和其药物组合物与用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
JP3040469B2 (ja) 1990-10-18 2000-05-15 セルプロ インコーポレイテッド 可撓性容器を用いて粒子を分離する装置及び方法
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
AU5310296A (en) 1995-03-17 1996-10-08 John Wayne Cancer Institute Detection of melanoma or breast metastases with a multiple marker assay
US5922836A (en) 1995-05-31 1999-07-13 Washington University Mammaglobin antigens
US5668267A (en) 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
US5985564A (en) * 1995-08-16 1999-11-16 President And Fellows Of Harvard College Assay for identifying agents that inhibit chromosome non-disjunction
US5986170A (en) 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
US5891857A (en) 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
EP0941328A1 (en) 1996-11-12 1999-09-15 Incyte Pharmaceuticals, Inc. Human breast tumor-specific proteins
JP2001509664A (ja) 1997-02-03 2001-07-24 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 乳ガン特異的遺伝子１
WO1998054963A2 (en) 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 human secreted proteins
EP1005544A4 (en) 1997-08-19 2004-07-14 Human Genome Sciences Inc 70 HUMAN, SECRETED PROTEINS
JP2002507387A (ja) * 1997-12-24 2002-03-12 コリクサ コーポレイション 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
ATE345387T1 (de) * 1998-03-18 2006-12-15 Corixa Corp Verbindungen und verfahren für therapie und diagnose von lungenkrebs
KR20070112860A (ko) * 1998-07-14 2007-11-27 코릭사 코포레이션 전립선 종양 단백질의 분리된 면역원성 부위 및 이를사용하여 전립선암을 진단하는 방법
CA2347906A1 (en) 1998-08-04 2000-02-17 Diadexus, Inc. A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
JP2002540761A (ja) 1999-01-21 2002-12-03 アボット・ラボラトリーズ 乳房の疾患を検出するために有用な試薬と方法
EP1259812A2 (en) 1999-05-28 2002-11-27 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
CA2390802A1 (en) 1999-11-23 2001-05-31 Diadexus, Inc. A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
WO2001047959A2 (en) 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof

Also Published As

Publication number Publication date
US6528054B1 (en) 2003-03-04
WO2001079286A2 (en) 2001-10-25
MXPA02010244A (es) 2003-05-23
JP5053497B2 (ja) 2012-10-17
WO2001079286A3 (en) 2003-01-30
NO20024972L (no) 2002-12-11
NO20024972D0 (no) 2002-10-16
CA2406213A1 (en) 2001-10-25
EP1299417A2 (en) 2003-04-09
RU2344831C2 (ru) 2009-01-27
AU2001255369A1 (en) 2001-10-30
NZ521865A (en) 2004-07-30
CN1646563A (zh) 2005-07-27
PL365244A1 (en) 2004-12-27
RU2002130715A (ru) 2004-03-27
JP2004520802A (ja) 2004-07-15
BR0110091A (pt) 2004-02-25

Similar Documents

Publication Publication Date Title
HUP0301740A2 (hu) Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
PT1349870E (pt) Composições para a terapêutica e diagnóstico do cancro do ovário
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
NO20004631D0 (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
HUP0103598A2 (hu) Készítmények és eljárások WT1-specifikus immunterápiás alkalmazásra
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
DE60045201D1 (de) C-Typ-Lektin-Transmembran-Antigen, das in menschlichem Prostatakrebs exprimiert wird, und Verwendungen dieses Antigens
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
HUP9903378A2 (hu) Az autoimmun betegségek immunterápiájában felhasználható autoantigének és ezekkel szerkezetileg rokon fehérjék
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
EP1715043A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
EA201591219A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
ES2279257T3 (es) Peptido del antigeno muc-1 para el desencadenamiento de una reaccion inmune frente a celulas tumorales.
ATE514780T1 (de) Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees